Tags : Hyrimoz

Biosimilars

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada

Shots: Health Canada has authorized Hyrimoz on Nov 4, 2020 for marketing in Canada. Hyrimoz has been approved for use in all same indications as reference Humira, including rheumatology, gastroenterology and dermatology A patient support program will be available to patients treated with Hyrimoz providing guidance with reimbursement navigation, financial assistance, administrative support & education […]Read More

Biosimilars Regulatory

Sandoz’s Hyrimoz (adalimumab) Receives EU Approval for Autoimmune Disorders

Shots: The approval is based on non-inferiority data assessing Hyrimoz vs reference biologic in patients with rheumatoid arthritis, plaque psoriasis, Crohn’s disease, uveitis and ulcerative colitis The study demonstrated in meeting al 1EPs and resulted bioequivalence in terms of safety, efficacy, PK, immunogenicity in patients with moderate to severe chronic plaque-type psoriasis Hyrimoz (adalimumab) is […]Read More